Hyphens Pharma

Hyphens Pharma secures Asean license for psoriasis treatment Wynzora Cream - THE EDGE SINGAPORE

Contracts

Hyphens Pharma secures Asean license for psoriasis treatment Wynzora Cream

Hyphens will pay MC2 a total of EUR2.5 million ($3.6 million), which includes an upfront payment and additional fees.

Results

Hyphens Pharma reports lower earnings of $8.57 million for FY2023 from heavier cost of sales

Hyphens Pharma's lower earnings of $8.57 million for FY2023 stem from heavier cost of sales, which increased by 9.2%.
Ardence Pharma deal favourable, analysts keep 'buy' on Hyphens Pharma - THE EDGE SINGAPORE

Broker's Calls

Ardence Pharma deal favourable, analysts keep 'buy' on Hyphens Pharma

Although the incremental net profit contribution is likely negligible near term, the deal presents cross-selling opportunities.

Company in the news

Hyphens Pharma to acquire remaining 58% of shares in Ardence Pharma, making it a wholly-owned subsidiary

Hyphens Pharma sees the acquisition as a way to strengthen its Malaysian presence, first tranche worth $1.86 million.

Deals, joint ventures & alliances

Hyphens Pharma's DocMed partners Hoang Duc to digitalise pharmaceutical supply chain in Vietnam

Hyphens Pharma forms JV with Hoang Duc to digitalise Vietnam's pharmaceutical supply chain.

Company in the news

Hyphens Pharma licenses topical drug for acne across all Southeast Asia

Hyphens Pharma called the drug a “game-changer” for acne sufferers as it is so far the only topical cream to treat hormonal acne.
After record 3QFY2022, CGS-CIMB lifts TP, EPS and dividend forecasts on Hyphens Pharma - THE EDGE SINGAPORE

Broker's Calls

After record 3QFY2022, CGS-CIMB lifts TP, EPS and dividend forecasts on Hyphens Pharma

Hyphens Pharma reported an almost threefold y-o-y jump in its 3QFY2022 profit after tax to $4.0 million.
Shares in Hyphens Pharma surge 11% as 3QFY2022 earnings see 270.8% jump - THE EDGE SINGAPORE

Results

Shares in Hyphens Pharma surge 11% as 3QFY2022 earnings see 270.8% jump

Shares in Hyphens Pharma have jumped some 10% in the morning following its stellar 3Q results.

Broker's Calls

PhillipCapital keeps ‘buy’ call on Hyphens Pharma as franchise expands with acquisitions

Hyphens Pharma’s revenue and patmi for the 1HFY2022 ended June stood at 54% and 67% of Chew’s FY2022 forecast respectively.
×